ABOUT PHARNEXT

Pharnext is an advanced clinical stage biopharmaceutical company developing new therapeutics that simultaneously target multiple key disease pathways for severe orphan and common neurological diseases. The proprietary R&D platform of Pharnext is based on network pharmacology. It allows the development of synergistic combinations of repositioned drugs – pleodrugs – which benefit from an outstanding safety profile and IP with strong enforceability. The company’s two lead pleodrugs are PXT-3003 for the treatment of Charcot-Marie-Tooth disease type 1A (Phase 2 completed) and PXT-864 for Alzheimer’s disease (Phase 2 ongoing) and other neurologic indications (Parkinson’s disease, amyotrophic lateral sclerosis).

Latest News

SYNERGISTIC EFFECTS WITH PXT-864 IN ALZHEIMER’S DISEASE
Thursday, 08 January 2015

SYNERGISTIC EFFECTS WITH PXT-864 IN ALZHEIMER’S DISEASE

Press Release (EN or FR)
Pleotherapy Proof of Concept in CMT-1A
Thursday, 18 December 2014

Pleotherapy Proof of Concept in CMT-1A

Press Release (EN or FR)
Michel de Rosen joins Pharnext Board of Directors
Tuesday, 09 December 2014

Michel de Rosen joins Pharnext Board of Directors

Press Release (EN or FR)
HNF Collaborates with Pharnext
Wednesday, 24 September 2014

HNF Collaborates with Pharnext

Press Release (EN or FR)